Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors

Journal of Hepatology

Volumn 40, Issue 5, 2004, Pages 792-798

  Notas, George ^a   Kolios, George ^a   Mastrodimou, Niki ^a   Kampa, Marilena ^a   Vasilaki, Anna ^a   Xidakis, Costas ^a   Castanas, Elias ^a   Thermos, Kyriaki ^a   Kouroumalis, Elias ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

Cortistatin mRNA; Hepatocellular carcinoma; Immunohistochemistry; Octreotide; Radioligand binding; RT PCR

Indexed keywords

CORTISTATIN; NEUROPEPTIDE; OCTREOTIDE; PHOSPHOTYROSINE; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER CELL CARCINOMA; MEMBRANE BINDING; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOASSAY; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEUROPEPTIDES; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; RNA, NEOPLASM; SOMATOSTATIN;

EID: 1942471034     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.01.016     Document Type: Article

References (45)

1. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol. 20:1999;157-198.
2. Pinzani P., Orlando C., Raggi C.C., Distante V., Valanzano R., Tricarico C., et al. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology. Regul Pept. 99:2001;79-86.
3. Oda Y., Tanaka Y., Naruse T., Sasanabe R., Tsubamoto M., Funahashi H. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today. 32:2002;690-694.
4. Dizeyi N., Konrad L., Bjartell A., Wu H., Gadaleanu V., Hansson J., Helboe L., Abrahamsson P.A. Localization of RNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol. 7:2002;91-98.
5. Papotti M., Croce S., Bello M., Bongiovanni M., Allia E., Schindler M., Bussolati G. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 439:2001;787-797.
6. Lamberts S.W., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 12:1991;450-482.
7. Zapata P.D., Ropero R.M., Valencia A.M., Buscail L., Lopez J.I., Martin-Orozco R.M., et al. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab. 87:2002;915-926.
8. Hatzoglou A., Bakogeorgou E., Papakonstanti E., Stournaras C., Emmanouel D.S., Castanas E. Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth. J Cell Biochem. 63:1996;410-421.
9. Lee J.U., Hosotani R., Wada M., Doi R., Koshiba T., Fujimoto K., et al. Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells. Eur J Cancer. 38:2002;1526-1534.
10. Ferjoux G., Bousquet C., Cordelier P., Benali N., Lopez F., Rochaix P., et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 94:2000;205-210.
11. de Lecea L., Ruiz-Lozano P., Danielson P.E., Peelle-Kirley J., Foye P.E., Frankel W.N., Sutcliffe J.G. Cloning, mRNA expression, and chromosomal mapping of mouse and human preprocortistatin. Genomics. 42:1997;499-506.
12. de Lecea L., Criado J.R., Prospero-Garcia O., Gautvik K.M., Schweitzer P., Danielson P.E., et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature. 381:1996;242-245.
13. Fukusumi S., Kitada C., Takekawa S., Kizawa H., Sakamoto J., Miyamoto M. Identification and characterization of a novel human cortistatin-like peptide. Biochem Biophys Res Commun. 232:1997;157-163.
14. 125I]Tyr10-cortistatin14 labels all five somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol. 357:1998;483-489.
15. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 35:2001;421-430.
16. Bajetta E., Procopio G., Buzzoni R., Catena L., Ferrari L., Del Vecchio M. Advances in diagnosis and therapy of neuroendocrine tumors. Expert Rev Anticancer Ther. 1:2001;371-381.
17. Freda P.U. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 87:2002;3013-3018.
18. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., Manousos O.N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 42:1998;442-447.
19. Raderer M., Hejna M.H., Muller C., Kornek G.V., Kurtaran A., Virgolini I. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol. 16:2000;1197-1201.
20. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Markidou S., et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 49:2002;1245-1250.
21. Yuen M.F., Poon R.T., Lai C.L., Fan S.T., Lo C.M., Wong K.W., et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 36:2002;687-691.
22. Jordan N.J., Kolios G., Abbot S.E., Sinai M.A., Thompson D.A., Petraki K., Westwick J. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. J Clin Invest. 104:1999;1061-1069.
23. Talme T., Ivanoff J., Hagglund M., Van Neerven R.J., Ivanoff A., Sundqvist K.G. Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3. Clin Exp Immunol. 125:2001;71-79.
24. Ejeskar K., Abel F., Sjoberg R., Backstrom J., Kogner P., Martinsson T. Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3→p36.2, but absence of mutations in primary tumors. Cytogenet Cell Genet. 89:2000;62-66.
25. Robas N., Mead E., Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem. 278:2003;44400-44404.
26. Thermos K., Reisine T. Somatostatin receptor subtypes in the clonal anterior pituitary cell lines AtT-20 and GH3. Mol Pharmacol. 33:1988;370-377.
27. Vasilaki A., Mouratidou M., Schulz S., Thermos K. Somatostatin mediates nitric oxide production by activating sst(2) receptors in the rat retina. Neuropharmacology. 43:2002;899-909.
28. Sperk G., Widmann R. Somatostatin precursor in the rat striatum: changes after local injection of kainic acid. J Neurochem. 45:1985;1441-1447.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:1983;55-63.
30. Dalm V.A., Van Hagen P.M., Van Koetsveld P.M., Langerak A.W., Van Der Lely A.J., Lamberts S.W., Hofland L.J. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J Clin Endocrinol Metab. 88:2003;270-276.
31. Kouroumalis E., Samonakis D., Skordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology. 37:2003;477.
32. Rabinowitz I., Telepak R., Lee F.C. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Clin Nucl Med. 27:2002;499-502.
33. Csaba Z., Bernard V., Helboe L., Bluet-Pajot M.T., Bloch B., Epelbaum J., Dournaud P. In vivo internalization of the somatostatin sst2A receptor in rat brain: evidence for translocation of cell-surface receptors into the endosomal recycling pathway. Mol Cell Neurosci. 17:2001;646-661.
34. Nouel D., Gaudriault G., Houle M., Reisine T., Vincent J.P., Mazella J., Beaudet A. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology. 138:1997;296-306.
35. Stroh T., Jackson A.C., Sarret P., Dal Farra C., Vincent J.P., Kreienkamp H.J., et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosisC. Endocrinology. 141:2000;354-365.
36. Dournaud P., Boudin H., Schonbrunn A., Tannenbaum G.S., Beaudet A. Interrelationships between somatostatin sst2A receptors and somatostatin- containing axons in rat brain: evidence for regulation of cell surface receptors by endogenous somatostatin. J Neurosci. 18:1998;1056-1071.
37. Reubi J.C., Waser B., Liu Q., Laissue J.A., Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab. 85:2000;3882-3891.
38. Spier A.D., de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Brain Res Rev. 33:2000;228-241.
39. Dalm V.A., Van Hagen P.M., Van Koetsveld P.M., Achilefu S., Houtsmuller A.B., Pols D.H., et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 285:2003;E344-E353.
40. Sanchez-Alavez M., Gomez-Chavarin M., Navarro L., Jimenez-Anguiano A., Murillo-Rodriguez E., Prado-Alcala R.A., et al. Cortistatin modulates memory processes in rats. Brain Res. 858:2000;78-83.
41. Deghenghi R., Papotti M., Ghigo E., Muccioli G. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest. 24:2001;RC1-RC3.
42. Cassoni P., Muccioli G., Marrocco T., Volante M., Allia E., Ghigo E., et al. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin. J Endocrinol Invest. 25:2002;362-368.
43. Chou C.K., Ho L.T., Ting L.P., Hu C.P., Su T.S., Chang W.C. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin. J Clin Invest. 79:1987;175-178.
44. Ballare E., Persani L., Lania A.G., Filopanti M., Giammona E., Corbetta S., et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 86:2001;3809-3814.
45. Hornick C.A., Anthony C.T., Hughey S., Gebhardt B.M., Espenan G.D., Woltering E.A. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 41:2000;1256-1263.